AxoGen, Inc. (AXGN) Earnings
AxoGen, Inc. is expected to report next earnings on August 4, 2026 (in NaN days), with a consensus EPS estimate of $0.09. AXGN has beaten EPS estimates in 8 of its last 12 reported quarters (average surprise -139.7% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Apr 28, 2026 | $0.12 | $0.07 | -41.7% | $61M | +6.2% |
| Feb 24, 2026 | $0.08 | $-0.28 | -450.4% | $60M | +0.0% |
| Oct 29, 2025 | $0.09 | $0.12 | +33.3% | $60M | +0.3% |
| May 8, 2025 | $-0.01 | $-0.02 | -100.0% | $49M | -9.0% |
| Feb 25, 2025 | $0.04 | $0.08 | +100.0% | $49M | +2.3% |
| Nov 7, 2024 | $0.01 | $0.07 | +1066.7% | $49M | +2.5% |
| Aug 8, 2024 | $-0.05 | $0.05 | +200.0% | $48M | +10.4% |
| May 2, 2024 | $-0.10 | $-0.06 | +40.0% | $41M | -4.6% |
| Mar 5, 2024 | $-0.09 | $-0.06 | +33.3% | $43M | +3.1% |
| Mar 14, 2023 | $-0.10 | $-0.03 | +70.0% | $36M | -0.1% |
| Aug 3, 2022 | $-0.15 | $-0.06 | +60.0% | $34M | +1.9% |
| May 4, 2022 | $-0.17 | $-0.20 | -17.6% | $31M | +2.2% |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q1 FY2026 · April 28, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
Michael discussed first quarter 2026 performance through six strategic plan priorities. Revenue growth and financial operating leverage: $61.5M revenue, 26.6% growth, adjusted EBITDA $5.7M, cash etc. $103.6M. Market development across extremities, oral, maxillofacial, head, neck, and breast: Extremities, OMF/head and neck, breast had growth. Commercial expansion: 146 sales reps, Salesforce productivity ahead of plan. Commercial excellence: High-potential accounts 60% of revenue, active surgeon count in high potential accounts increased, professional education programs conducted. Standard care objectives: Progress expanding commercial coverage, Cigna extended coverage, Elevance made changes but with criteria. Innovation, R&D, therapeutic reconstruction: Three focus areas.
Guidance
Raised full year 2026 revenue guidance to at least 20% or total revenue of at least $270 million. Full-year gross margin expected 74% - 76%, expected to be free cash flow positive for full year 2026. Guide reflects confidence in commercial execution and Salesforce productivity improvements, not including material benefit from payer coverage decisions beyond known.
Segment performance
First quarter 2026 revenue was $61.5 million, 26.6% growth year-over-year. Adjusted EBITDA was $5.7 million. Extremities had double-digit year-over-year growth, OMF and head, neck, and breast had double-digit growth, breast was the fastest growing with double-digit growth. High-potential accounts represented 60% of total revenue for the first quarter, growth from high-potential accounts was 48% of total revenue growth in the quarter. Gross margin in first quarter was 75.2%, full-year gross margin guidance 74% - 76%.
Risks & headwinds
Forward-looking statements subject to risks and uncertainties in company filings, including those in Form 10-K, 10-Q, etc. Payers' coverage criteria and utilization management criteria could impact business. Clinical study progress and data maturation could affect plans.
Analyst Q&A
Q: Questions on guidance deceleration, reimbursement coverage impact, growth drivers, prostate clinical signals, commercial coverage restrictions, sales rep breakdown, gross margin cadencing, M&A opportunities, growth breakdown.
A: Responses on comparables, coverage impact not immediate, growth from strategic plan activities, prostate readout timing, coverage criteria issues, sales rep details, gross margin cadencing, M&A consideration, growth broad-based.